Supporting the mental health and wellbeing of over 4 million people in Australia living with cardiovascular disease (CVD) is crucial to them avoiding further heart attacks or strokes.
Arrowhead shelves one cardiometabolic drug candidate, focuses on another
On Tuesday, Arrowhead Pharmaceuticals said it will shift focus to its experimental cardiometabolic drug plozasiran and will deprioritize its work on zodasiran, emphasizing the need